10-K · February 24, 2026
Iovance is shifting from development to commercialization with Amtagvi® (lifileucel) as its primary commercial product and Proleukin® as a complementary product. The company reports improving commercial metrics and…
Earnings analysis · 10-Q
IOVA earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Iovance Biotherapeutics reported strong Q1 results, with total revenue increasing to $71.4 million, up 45% from $49.3 million in the prior year. The company continues to expand its commercial efforts for Amtagvi® and…
Read full summary
Iovance Biotherapeutics reported strong Q1 results, with total revenue increasing to $71.4 million, up 45% from $49.3 million in the prior year. The company continues to expand its commercial efforts for Amtagvi® and Proleukin®, although significant net losses persist at $79 million. Notable reductions in R&D expenses contributed to improved financial metrics, while ongoing regulatory and operational challenges highlight the complexity of the cell therapy market.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Revenue Growth of 45% YoY
Total revenue for Q1 reached $71.4 million, up from $49.3 million in Q1 2025.
-
Net Loss Reduction of 32%
Net loss decreased by $37.1 million, from $116.2 million in Q1 2025 to $79 million.
-
Operating Expenses Decreased
Total costs and expenses dropped to $152.5 million, down 11% compared to Q1 2025.
-
Definitive Progress on Clinical Trials
The FDA lifted the clinical hold on IOV-LUN-202, allowing enrollment to resume.
-
Strong Cash Position at $319.4M
Cash, cash equivalents, and investments stood at $319.4 million as of March 31, 2026.
-
Plans for Future Clinical Trials Announced
Iovance announced plans to commence a registrational trial in advanced UPS and DDLPS in Q2 2026.
What to watch
-
Continued High Net Losses
Despite revenue growth, the company reported a net loss of $79 million, indicating ongoing profitability challenges.
-
Regulatory Delays
The continued uncertainty and complexity surrounding regulatory approvals could hinder future earnings.
-
Dependence on Third-Party Manufacturing
Future clinical trials and product availability are heavily reliant on third-party manufacturers, posing significant risks.
Management's outlook
No numeric guidance provided; management emphasizes continued revenue growth from commercial product launches.
Earlier filings 4
10-Q · November 6, 2025
Iovance reported Q3 2025 product revenue of $67.455M (up from $58.555M in Q3 2024) and delivered EPS of $(0.25) versus $(0.28) a year ago. Gross margin declined to ~43.0% from 46.2% y/y, while operating loss remained…
10-Q · August 7, 2025
Iovance reported product revenue of $59.95M in Q2 2025 (vs. $31.11M in Q2 2024), driving total six-month revenue of $109.28M. Profitability remains challenged: gross margin is only 5.5% and operating margin is -189.8%,…
10-Q · May 8, 2025
Iovance reported first-quarter product revenue of $49.324 million and GAAP net loss of $116.163 million (EPS -$0.36). The quarter shows commercialization progress (product revenue up from $715,000 in Q1 2024) but…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.